Theriva Biologics Inc
TOVX0.195USD
-0.008-4.14%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.00MMarket Cap
0.09P/E TTM
More Details of Theriva Biologics Inc Company
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Theriva Biologics Inc Info
Ticker SymbolTOVX
Company nameTheriva Biologics Inc
IPO dateFeb 12, 1993
CEOShallcross (Steven A)
Number of employees22
Security typeOrdinary Share
Fiscal year-endFeb 12
Address9605 Medical Center Drive, Suite 270
CityROCKVILLE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code20850
Phone17343327800
Websitehttps://therivabio.com/
Ticker SymbolTOVX
IPO dateFeb 12, 1993
CEOShallcross (Steven A)
Company Executives of Theriva Biologics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
35.83K
+173.54%
Dr. John Monahan, Ph.D.
Dr. John Monahan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Independent Director
Independent Director
--
--
Mr. Chris Calabrese
Mr. Chris Calabrese
IR Contact Officer
IR Contact Officer
--
--
Mr. Jeffrey J. (Jeff) Kraws
Mr. Jeffrey J. (Jeff) Kraws
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
35.83K
+173.54%
Dr. John Monahan, Ph.D.
Dr. John Monahan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Independent Director
Independent Director
--
--
Mr. Chris Calabrese
Mr. Chris Calabrese
IR Contact Officer
IR Contact Officer
--
--
Mr. Jeffrey J. (Jeff) Kraws
Mr. Jeffrey J. (Jeff) Kraws
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Jeffrey Matthew Gryga Irrevocable Trust
2.19%
Ikarian Capital LLC
0.36%
Two Sigma Investments, LP
0.26%
Jane Street Capital, L.L.C.
0.11%
Virtu Americas LLC
0.11%
Other
96.97%
Shareholders
Shareholders
Proportion
Jeffrey Matthew Gryga Irrevocable Trust
2.19%
Ikarian Capital LLC
0.36%
Two Sigma Investments, LP
0.26%
Jane Street Capital, L.L.C.
0.11%
Virtu Americas LLC
0.11%
Other
96.97%
Shareholder Types
Shareholders
Proportion
Corporation
2.19%
Hedge Fund
0.67%
Research Firm
0.22%
Investment Advisor/Hedge Fund
0.19%
Investment Advisor
0.17%
Individual Investor
0.11%
Venture Capital
0.10%
Other
96.36%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
46
323.11K
0.96%
-713.60K
2025Q2
48
1.10M
12.39%
+651.18K
2025Q1
49
857.41K
15.86%
+431.26K
2024Q4
47
288.41K
10.39%
-386.06K
2024Q3
46
870.16K
32.73%
+793.17K
2024Q2
44
68.69K
8.12%
+12.48K
2024Q1
47
44.91K
6.55%
-20.95K
2023Q4
50
55.33K
8.08%
-10.69K
2023Q3
53
56.83K
8.38%
-11.75K
2023Q2
52
54.61K
8.12%
-13.58K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ikarian Capital LLC
120.03K
1.25%
--
--
Jun 30, 2025
Two Sigma Investments, LP
17.82K
0.19%
+17.82K
--
Jun 30, 2025
Virtu Americas LLC
34.49K
0.36%
+34.49K
--
Jun 30, 2025
Shallcross (Steven A)
13.10K
0.14%
+3.10K
+31.00%
Jul 08, 2025
Boothbay Fund Management, LLC
35.60K
0.37%
--
--
Jun 30, 2025
XTX Markets LLC
17.19K
0.18%
+17.19K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
18.60K
0.19%
-82.00
-0.44%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 16, 2024
Merger
25→1
Aug 16, 2024
Merger
25→1
Aug 16, 2024
Merger
25→1
Aug 16, 2024
Merger
25→1
Jul 15, 2022
Merger
10→1
Jul 15, 2022
Merger
10→1
Date
Type
Ratio
Aug 16, 2024
Merger
25→1
Aug 16, 2024
Merger
25→1
Aug 16, 2024
Merger
25→1
Aug 16, 2024
Merger
25→1
Jul 15, 2022
Merger
10→1
Jul 15, 2022
Merger
10→1
Jul 15, 2022
Merger
10→1
Jul 15, 2022
Merger
10→1
FAQs
Who are the top five shareholders of Theriva Biologics Inc?
The top five shareholders of Theriva Biologics Inc are:
Ikarian Capital LLC holds 120.03K shares, accounting for 1.25% of the total shares.
Two Sigma Investments, LP holds 17.82K shares, accounting for 0.19% of the total shares.
Virtu Americas LLC holds 34.49K shares, accounting for 0.36% of the total shares.
Shallcross (Steven A) holds 13.10K shares, accounting for 0.14% of the total shares.
Boothbay Fund Management, LLC holds 35.60K shares, accounting for 0.37% of the total shares.
Ikarian Capital LLC holds 120.03K shares, accounting for 1.25% of the total shares.
Two Sigma Investments, LP holds 17.82K shares, accounting for 0.19% of the total shares.
Virtu Americas LLC holds 34.49K shares, accounting for 0.36% of the total shares.
Shallcross (Steven A) holds 13.10K shares, accounting for 0.14% of the total shares.
Boothbay Fund Management, LLC holds 35.60K shares, accounting for 0.37% of the total shares.
What are the top three shareholder types of Theriva Biologics Inc?
The top three shareholder types of Theriva Biologics Inc are:
Jeffrey Matthew Gryga Irrevocable Trust
Ikarian Capital LLC
Two Sigma Investments, LP
Jeffrey Matthew Gryga Irrevocable Trust
Ikarian Capital LLC
Two Sigma Investments, LP
How many institutions hold shares of Theriva Biologics Inc (TOVX)?
As of 2025Q3, 46 institutions hold shares of Theriva Biologics Inc, with a combined market value of approximately 323.11K, accounting for 0.96% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -11.44%.
What is the biggest source of revenue for Theriva Biologics Inc?
In --, the -- business generated the highest revenue for Theriva Biologics Inc, amounting to -- and accounting for --% of total revenue.
